Bioymifi --- TRAIL Receptor DR5 Activator

Bioss

Bioymifi --- TRAIL Receptor DR5 Activator [1420071-30-2]

16

Research Use Only

98.0

Bioymifi is a potent and selective small molecule agonist of DR5, identified by a high-throughput chemical screening for compounds that promote cell death in synergy with a small-molecule mimetic of Smac. Bioymifi directly targets DR5, specifically binds the ECD of DR5 (Kd ~1.2 microM), and induces the formation of DR5 aggregates and DR5 activation. Bioymifi induces caspase-8-dependent apoptosis, which occurs through a DR5-dependent extrinsic pathway but independent of TRAIL. Bioymifi is capable of acting as a single agent to induce DR5 clustering and aggregation, leading to apoptosis without the need for a Smac mimetic in a variety of cancer cell lines, even in U2OS and HT29 cell lines. Bioymifi could be a potential lead compound for the development of small-molecule TRAIL mimics targeting DR5 for cancer therapy.

-20°C

51202000